{
  "timestamp": "2025-10-30T00:10:40.554512",
  "procedure_summary": "Chemotherapy - ",
  "confidence_score": 0.8999999999999999,
  "organs_analyzed": [
    {
      "organ_name": "heart",
      "affected_by_procedure": true,
      "at_risk": true,
      "risk_level": "moderate",
      "pathways_involved": [
        "pathway_not_specified"
      ],
      "known_recommendations": [
        "**Baseline Assessment:** Complete cardiovascular evaluation including echocardiography or MUGA scan to establish baseline LVEF before chemotherapy initiation",
        "**Serial Monitoring:** Regular cardiac imaging during treatment (frequency depends on specific agent and cumulative dose)",
        "**Biomarker Surveillance:** Troponin and BNP/NT-proBNP monitoring can detect subclinical cardiotoxicity",
        "**ECG Monitoring:** Essential for detecting arrhythmias, particularly QTc prolongation",
        "**Dose Modification:** Limiting cumulative anthracycline doses (e.g., doxorubicin <400-450 mg/m\u00b2)",
        "**Infusion Duration:** Extended infusion protocols reduce peak plasma concentrations",
        "**Treatment Scheduling:** Adequate intervals between cardiotoxic cycles",
        "**Risk Stratification:** Adjusting protocols based on pre-existing cardiac disease",
        "**Dexrazoxane:** FDA-approved iron chelator for anthracycline cardioprotection (reduces oxidative stress)",
        "**Liposomal Formulations:** Pegylated liposomal doxorubicin shows reduced cardiotoxicity",
        "**Pharmacological Prophylaxis:** ACE inhibitors/ARBs and beta-blockers show promise in high-risk patients",
        "**Lifestyle Modifications:** Blood pressure control, diabetes management, smoking cessation",
        "*Pathway Considerations:**",
        "Oxidative stress and mitochondrial dysfunction (anthracyclines)",
        "Topoisomerase-2\u03b2 inhibition in cardiomyocytes",
        "Direct myocardial damage and apoptosis",
        "Vascular endothelial dysfunction",
        "*Risk Mitigation Framework:**",
        "**Pre-existing cardiac disease:** Consider alternative regimens or aggressive prophylaxis",
        "**Arrhythmia risk:** Electrolyte monitoring, QTc surveillance, avoid QT-prolonging co-medications",
        "**Multidisciplinary approach:** Cardio-oncology consultation for high-risk patients",
        "*Limitations:**",
        "Optimal monitoring frequency protocols",
        "Standardized intervention thresholds",
        "Long-term surveillance strategies",
        "Comparative effectiveness of various cardioprotective agents",
        "*Rationale for Confidence Level:**",
        "Lack of specification regarding chemotherapy type limits precision of recommendations",
        "Individual patient factors significantly influence outcomes",
        "Exact agents being used (anthracyclines, HER2-targeted, platinum-based, etc.)",
        "Planned cumulative doses",
        "Treatment schedule and duration",
        "Baseline cardiac function (LVEF, prior cardiac history)",
        "Age and comorbidities (hypertension, diabetes, prior radiation)",
        "Concurrent medications",
        "Previous cardiotoxic therapy exposure",
        "ASCO Clinical Practice Guidelines on Prevention and Monitoring of Cardiac Dysfunction",
        "ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity",
        "ESMO Clinical Practice Guidelines for Cardiac Monitoring",
        "Systematic reviews on cardioprotective interventions",
        "Comparative effectiveness studies of monitoring strategies",
        "Long-term outcome data from cardio-oncology registries",
        "Local cardio-oncology program guidelines",
        "Available monitoring resources and expertise",
        "Formulary availability of cardioprotective agents"
      ],
      "potential_recommendations": [
        "Pre-procedure cardiac risk stratification",
        "Consider prophylactic medications for high-risk patients"
      ],
      "debunked_claims": [
        "Routine beta-blockers are not recommended for all patients",
        "Prophylactic antiarrhythmics are not routinely indicated"
      ],
      "evidence_quality": "limited"
    },
    {
      "organ_name": "lung",
      "affected_by_procedure": true,
      "at_risk": true,
      "risk_level": "low",
      "pathways_involved": [
        "pathway_not_specified"
      ],
      "known_recommendations": [
        "*Primary Recommendations:**",
        "Platinum-based doublet chemotherapy (cisplatin/carboplatin + pemetrexed, paclitaxel, or gemcitabine) is standard for advanced stages",
        "Adjuvant chemotherapy post-surgery improves survival in stages II-III",
        "Often combined with immunotherapy (pembrolizumab) or targeted therapy based on molecular markers",
        "Platinum-etoposide combination is first-line standard",
        "Highly chemosensitive initially, though recurrence is common",
        "Combined with radiation for limited-stage disease",
        "*Critical Considerations:**",
        "**Medical supervision is essential** (correctly noted in input) - requires oncology specialist management",
        "**Biomarker testing mandatory** before treatment selection (EGFR, ALK, ROS1, PD-L1)",
        "**Performance status assessment** determines treatment intensity",
        "**Risk-benefit analysis** must account for: stage, histology, comorbidities, patient preferences",
        "*Risk Profile:**",
        "Common: Myelosuppression, nausea, fatigue, neuropathy",
        "Serious: Infection risk, organ toxicity (renal, cardiac), treatment-related mortality (~1-3%)",
        "Long-term: Secondary malignancies, chronic organ damage",
        "*Modern Context:**",
        "*Rationale for confidence level:**",
        "**High confidence (0.85)** in chemotherapy's established role in lung cancer treatment",
        "Reduced from 0.95 due to:",
        "Lack of specific pathway information (staging, histology, molecular profile)",
        "\"Limited quality\" notation requiring verification",
        "Rapidly evolving treatment landscape requiring current guidelines",
        "Lung cancer stage (I-IV)",
        "Histological subtype (adenocarcinoma, squamous cell, SCLC, other)",
        "Molecular/biomarker profile (EGFR, ALK, ROS1, BRAF, PD-L1 expression)",
        "Performance status (ECOG/Karnofsky score)",
        "Prior treatments and response",
        "NCCN Guidelines for NSCLC and SCLC (2024)",
        "ASCO Clinical Practice Guidelines",
        "ESMO Clinical Practice Guidelines for lung cancer",
        "Meta-analyses of platinum-based chemotherapy efficacy",
        "Comparative effectiveness studies (chemotherapy vs. chemoimmunotherapy)",
        "Quality of life studies in lung cancer chemotherapy",
        "Patient comorbidity profile",
        "Organ function tests (renal, hepatic, cardiac)",
        "Previous chemotherapy exposure and toxicities",
        "Local formulary and regimen preferences",
        "Supportive care protocols",
        "Monitoring schedules and dose modification guidelines",
        "*Recommendation:** Chemotherapy is appropriate for lung cancer under proper medical supervision, but specific regimen selection requires comprehensive patient evaluation and current guideline consultation."
      ],
      "potential_recommendations": [
        "Standard potential recommendations"
      ],
      "debunked_claims": [
        "Standard debunked recommendations"
      ],
      "evidence_quality": "limited"
    },
    {
      "organ_name": "kidneys",
      "affected_by_procedure": true,
      "at_risk": true,
      "risk_level": "high",
      "pathways_involved": [
        "pathway_not_specified"
      ],
      "known_recommendations": [
        "*PROVEN INTERVENTIONS:**",
        "**Aggressive hydration protocols** (0.9% saline pre/post-infusion) - Standard of care for cisplatin, high-dose methotrexate, and ifosfamide",
        "**Dose adjustments** based on eGFR/creatinine clearance for renally-cleared agents",
        "**Monitoring protocols** - Serial creatinine, electrolytes, urinalysis before each cycle",
        "**Avoidance of concurrent nephrotoxins** (NSAIDs, aminoglycosides, contrast agents when possible)",
        "*AGENT-SPECIFIC CONSIDERATIONS:**",
        "Methotrexate: Urinary alkalinization, leucovorin rescue",
        "Ifosfamide: Mesna for hemorrhagic cystitis prevention (indirect renal protection)",
        "*LIMITATIONS:**",
        "Direct tubular toxicity (cisplatin, ifosfamide)",
        "Crystal nephropathy (methotrexate)",
        "Thrombotic microangiopathy (mitomycin C, gemcitabine)",
        "Glomerular injury (bevacizumab)",
        "Limited high-quality RCTs for many protective strategies",
        "Optimal hydration volumes/rates not standardized across all agents",
        "Biomarkers (NGAL, KIM-1) for early AKI detection not yet standard practice",
        "Long-term CKD progression data following chemotherapy-induced AKI incomplete",
        "Implement aggressive IV hydration protocols",
        "Calculate baseline renal function and adjust doses accordingly",
        "Monitor renal function before each cycle",
        "Discontinue nephrotoxic co-medications",
        "Consider agent-specific interventions (alkalinization, electrolyte replacement)",
        "Nephrology consultation for eGFR <60 mL/min/1.73m\u00b2",
        "Extended monitoring intervals for high-risk patients",
        "No pathway specification prevents mechanism-targeted recommendations (\u00b10.08)",
        "Individual patient factors not provided (comorbidities, concurrent medications)"
      ],
      "potential_recommendations": [
        "Novel biomarkers for early detection",
        "Pharmacogenomic testing for susceptibility",
        "Targeted cytoprotective agents (context-dependent)",
        "*Rationale for Confidence Level:**",
        "**Strengths:** Risk factors and basic protective measures are well-established in nephrology literature",
        "**Limitations:**",
        "Lack of specific chemotherapy agent reduces precision (\u00b10.15)"
      ],
      "debunked_claims": [
        "Furosemide does not prevent contrast nephropathy",
        "Dopamine is not protective and may be harmful"
      ],
      "evidence_quality": "limited"
    },
    {
      "organ_name": "liver",
      "affected_by_procedure": true,
      "at_risk": true,
      "risk_level": "low",
      "pathways_involved": [
        "pathway_not_specified"
      ],
      "known_recommendations": [
        "**Pre-treatment assessment**: Liver function tests (AST, ALT, bilirubin, albumin, PT/INR) are mandatory",
        "**Agent selection**: Choose chemotherapy with consideration of hepatic metabolism pathway",
        "**Dose adjustment**: Follow established guidelines (e.g., NCI, ASCO) for hepatic impairment",
        "**Monitoring**: Serial liver function testing during treatment",
        "**Supportive care**: Hepatoprotective strategies when indicated",
        "Pathway not specified limits agent-specific recommendations",
        "Quality marked as \"limited\" suggests need for individualized assessment",
        "Pharmacokinetic data varies significantly between chemotherapy classes",
        "Limited prospective trials in severe hepatic dysfunction populations",
        "*Clinical Decision Framework:**",
        "Normal liver function \u2192 Standard protocols with routine monitoring",
        "Severe liver disease \u2192 Requires multidisciplinary evaluation, dose modification, alternative regimens, or contraindication depending on specific agent and disease severity",
        "*Rationale for Confidence Level:**",
        "Lack of specific pathway and agent information limits precision (decreases confidence)",
        "Well-established clinical guidelines exist for hepatic dose adjustments (increases confidence)"
      ],
      "potential_recommendations": [
        "Standard potential recommendations"
      ],
      "debunked_claims": [
        "Standard debunked recommendations"
      ],
      "evidence_quality": "limited"
    }
  ],
  "general_recommendations": [
    "Consult healthcare provider before procedure",
    "Follow all pre-procedure instructions",
    "Monitor for adverse effects post-procedure"
  ],
  "research_gaps": [
    "Long-term effects need further study",
    "Optimal protocols under investigation"
  ],
  "reasoning_steps_count": 5
}